UK’s NICE Endorses First Sickle Cell Disease Drug in Two Decades

October 11, 2021

The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service (NHS) offer Novartis’ Adakveo (crizanlizumab) as a treatment for sickle cell disease — the first time in 20 years the cost regulator has supported a new treatment for the disease.

Adakveo was endorsed as a preventive treatment for recurrent sickle cell disease in people 16 years and older because the treatment leads to significantly fewer sickle cell crises in a year than in patients given standard of care.

NICE did not disclose the discount the NHS would be receiving for offering the drug, which has a list price in the UK of $1,413 per 10ml dose. Patients may receive three or four doses per month, which would mean an annual cost of between $50,868 and $67,824 before any discounts.

View today's stories